1. Metabolic Research Unit, School of Medicine, Deakin University, Geelong and
2. Baker IDI Heart and Diabetes Institute, Melbourne, Australia;
3. Southwest Foundation for Biomedical Research, San Antonio, Texas; and
4. Verva Pharmaceuticals and
5. ChemGenex Pharmaceuticals, Geelong;
6. Diabetes and Obesity Research Program, Garvan Institute, Sydney; and
7. Institute of Technology and Research Innovation, Deakin University, Geelong, Australia